BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

Allogene Therapeutics (ALLO)Allogene TherapeuticsFinancing

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock.

Related news

ALLOAllogene Therapeutics2026-04-16 20:01 EST

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

ALLOAllogene Therapeutics2026-04-15 01:50 EST

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

MBIOMustang Bio2025-02-10 13:00 EST

Mustang Bio Announces Closing of $8 Million Public Offering

MBIOMustang Bio2025-02-06 12:00 EST

Mustang Bio Announces Pricing of $8 Million Public Offering

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

ALLOAllogene Therapeutics2026-08-12 20:05 EST

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-08-04 12:30 EST

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-07-29 12:30 EST

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

ALLOAllogene Therapeutics2026-07-15 12:30 EST

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLOAllogene Therapeutics2026-05-28 21:02 EST

Allogene Therapeutics Announces Planned CEO Succession

Stock data

Close
2.09 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States